Earnings Call Summary | Crawford-B(CRD.B.US) Q4 2023 Earnings Conference
Earnings Call Summary | Crawford-B(CRD.B.US) Q4 2023 Earnings Conference
The following is a summary of the Crawford & Company (CRD.B) Q4 2023 Earnings Call Transcript:
Financial Performance:
Crawford & Company reported Q4 2023 revenues of $296.1 million, a decrease of 8% from the previous year.
GAAP net loss was $800K, which is a vast improvement from the $14.1 million loss in Q4 2022.
The company's non-GAAP operating earnings stood at $7.8 million and adjusted EBITDA was at $15.7 million for Q4 2023.
Total debt outstanding by 2023-end showcased a decrease at $209.1 million, a dip from $238.9 million at the end of 2022.
The firm managed to generate free cash flow of $67.2 million for 2023.
The dividends per share increased to $0.26 in 2023, compared to $0.24 in 2022.
Business Progress:
Decreased revenues in the North America segment were attributed to milder weather, whereas international operations reported a 9.9% increase.
Broadspire revenues surged by 17.2%, driven by new business development, increased medical management usage, and pricing improvements.
The company is actively looking for potential M&A opportunities and aims to reduce its leverage to provide financial strength and flexibility.
The firm is well positioned for growth in the weather-dependent business due to increasing frequency and severity of weather events and is capitalizing on carrier claims outsourcing due to increased claim volume and staffing challenges.
Crawford added more than $100 million in new/increased business for the third consecutive year in 2023, and is seeking compelling acquisition targets to broaden capabilities.
More details: Crawford-B IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
The following is a summary of the Crawford & Company (CRD.B) Q4 2023 Earnings Call Transcript:
以下是克勞福德公司(CRD.B)2023年第四季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Crawford & Company reported Q4 2023 revenues of $296.1 million, a decrease of 8% from the previous year.
GAAP net loss was $800K, which is a vast improvement from the $14.1 million loss in Q4 2022.
The company's non-GAAP operating earnings stood at $7.8 million and adjusted EBITDA was at $15.7 million for Q4 2023.
Total debt outstanding by 2023-end showcased a decrease at $209.1 million, a dip from $238.9 million at the end of 2022.
The firm managed to generate free cash flow of $67.2 million for 2023.
The dividends per share increased to $0.26 in 2023, compared to $0.24 in 2022.
克勞福德公司報告稱,2023年第四季度收入爲2.961億美元,比上年下降8%。
GAAP淨虧損爲80萬美元,與2022年第四季度的1,410萬美元虧損相比有了很大的改善。
該公司的非公認會計准則營業收益爲780萬美元,2023年第四季度調整後的息稅折舊攤銷前利潤爲1,570萬美元。
到2023年底,未償債務總額從2022年底的2.389億美元下降至2.091億美元。
該公司設法在2023年創造了6,720萬美元的自由現金流。
每股股息在2023年增加到0.26美元,而2022年爲0.24美元。
Business Progress:
業務進展:
Decreased revenues in the North America segment were attributed to milder weather, whereas international operations reported a 9.9% increase.
Broadspire revenues surged by 17.2%, driven by new business development, increased medical management usage, and pricing improvements.
The company is actively looking for potential M&A opportunities and aims to reduce its leverage to provide financial strength and flexibility.
The firm is well positioned for growth in the weather-dependent business due to increasing frequency and severity of weather events and is capitalizing on carrier claims outsourcing due to increased claim volume and staffing challenges.
Crawford added more than $100 million in new/increased business for the third consecutive year in 2023, and is seeking compelling acquisition targets to broaden capabilities.
北美板塊收入下降歸因於天氣溫和,而國際業務則增長了9.9%。
受新業務發展、醫療管理使用量增加和定價改善的推動,Broadspire的收入激增了17.2%。
該公司正在積極尋找潛在的併購機會,旨在降低其槓桿率以提供財務實力和靈活性。
由於天氣事件的頻率和嚴重性增加,該公司完全有能力在依賴天氣的業務中實現增長,並且由於索賠量增加和人員配置方面的挑戰,該公司正在利用承運人的索賠外包。
克勞福德在2023年連續第三年增加了超過1億美元的新增/增長業務,並且正在尋求引人注目的收購目標以擴大能力。
More details: Crawford-B IR
更多詳情: Crawford-B 紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧